US LNG exports surge but will buyers in China turn up?
CAMBRIDGE, UK - Sareum Holdings PLC (AIM: SAR), the biotech firm specializing in kinase inhibitors for cancer and autoimmune diseases, disclosed that Dr. Stephen Parker, the company’s Executive Chairman, has increased his stake in the company. On Monday, Dr. Parker acquired 84,033 ordinary shares at an average price of 11.9 pence per share.
Following this transaction, Dr. Parker’s combined direct and indirect shareholding in Sareum amounts to approximately 0.30% of the company’s issued share capital, totaling 405,045 ordinary shares. Additionally, Dr. Parker has voting rights discretion over 25,680 ordinary shares held by persons connected to him.
The purchase took place on the London Stock Exchange (LON:LSEG)’s AIM market, according to the notification made in line with the Market Abuse Regulation. The company has classified this information as inside information under the Market Abuse Regulations (EU) No. 596/2014, which continues to be part of UK law post-Brexit.
This move by Dr. Parker demonstrates a commitment to the company by one of its key executives, and it may be of interest to investors watching the company’s leadership’s investment actions. Sareum Holdings has not provided further details on the transaction or any additional comments on its future plans or prospects.
This announcement is based on a press release statement issued by Sareum Holdings PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.